Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 15 | 01 | Page :
    By

    Yash Prakash Rathod,

  • Pranav Dattatray Farate,

  • Dilan Philip Kurian1,

  • Ashlesha Shripad Mandale1,

  • Himalay Prassan Shende1,

  • Priya Shekhar Daingade2,

  • Vaishali Ganesh Mundhe,

  • Tushar Treembak Shelke,

  1. Student,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  2. Student,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  3. Student,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  4. Student,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  5. Student,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  6. Assistant Professor,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  7. Assistant Professor,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India
  8. Principal,, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi, Department of Pharmacy, Genba Sopanrao Moze College of Pharmacy, Wagholi,, Pune, Maharashtra,, India

Abstract

Pharmacovigilance, or PV, is “the pharmacological science relating to the detection, assessment, understanding, and prevention of adverse effects, mainly long term and short-term adverse effects of medicines.” PV’s specific objectives are to increase patient care and safety when using medications and all medical and paramedical therapies; assist in evaluating the benefits, drawbacks, efficacy, and risks of medications, ensuring their safe, prudent, and more effective use; and promote clinical training, education, and pharmacovigilance, as well as its successful public dissemination. Pharmacovigilance (PV) is the main and most important component of clinical research that aims to lower the risk of drug-related accidents for patients. The aim of this article is to give a brief overview regarding the value of the practice of PV to determine and maintain the rational use of medications in the field of pharmacotherapy. Pharmacovigilance (PV) is crucial for public health, mainly for monitoring and assessing adverse drug reactions to ensure patient health. Artificial intelligence (AI) integration is transforming PV by enabling massive data analysis, automating processes, and enhancing the detection of safety signals. This increased capability results in the implementation of more extensive and proactive risk management. An essential “sunshade” of medication safety, pharmacovigilance (PV) guarantees smooth and efficient drug relation, clinical practice, and public health initiatives around the world by monitoring and evaluating the adverse drug reactions (ADRs). PV provides solutions to major drug safety issues which may affect public health across borders. Although many PV centers around the world are now monitoring drug safety, the start of the millennium presented major challenges to enhance drug safety and surveillance. This article discusses drug safety, the function and limitation of global PV centers, and future PV thinking in healthcare. The pharmaceutical industry concentrates on case management, signal detection, and benefit-risk management. These are essential for post-marketing surveillance, product safety, and appropriate medical use through risk management.

Keywords: Keywords: Adverse drug reaction (ADR), artificial intelligence (AI), biomarkers, genomic study, pharmacovigilance, wearable devices.

How to cite this article:
Yash Prakash Rathod, Pranav Dattatray Farate, Dilan Philip Kurian1, Ashlesha Shripad Mandale1, Himalay Prassan Shende1, Priya Shekhar Daingade2, Vaishali Ganesh Mundhe, Tushar Treembak Shelke. Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety. Research and Reviews : Journal of Computational Biology. 2026; 15(01):-.
How to cite this URL:
Yash Prakash Rathod, Pranav Dattatray Farate, Dilan Philip Kurian1, Ashlesha Shripad Mandale1, Himalay Prassan Shende1, Priya Shekhar Daingade2, Vaishali Ganesh Mundhe, Tushar Treembak Shelke. Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety. Research and Reviews : Journal of Computational Biology. 2026; 15(01):-. Available from: https://journals.stmjournals.com/rrjocb/article=2026/view=237934


References

  1. Dol HS, Shinde VR, Vijaykumar Mali J, Navnath Khakal N. Pharmacovigilance: A practical approach for reshaping patient safety. Innovare J Med Sci. 2017;5(2):1–4.
  2. Kumar DA, Reddenna L, Basha SA. Pharmacovigilance programme of India. Innov Pharm. 2015;6(1).
  3. Ahire YS, Patil JH, Chordiya HN, Deore RA, Bairagi VA. Advanced applications of artificial intelligence in pharmacovigilance: Current trends and future perspectives. J Pharm Res. 2024;23(1):23–33.
  4. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–20.
  5. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: Use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105(4):954–61.
  6. Sumit K, Ashish B. Pharmacovigilance in India: Perspectives and prospects. J Drug Deliv Ther. 2013;3(4):237–46.
  7. Vishwakarma R, Rai V, Singh S. A review paper on pharmacovigilance: an overview. 2024;4:60–70.
  8. Ghosh R, Kempf D, Pufko A, Barrios Martinez LF, Davis CM, Sethi S. Automation opportunities in pharmacovigilance: An industry survey. Pharm Med. 2020;34:7–18.
  9. Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices. Perspect Clin Res. 2018;9(4):170–4.
  10. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, et al. Artificial intelligence based on machine learning in pharmacovigilance: A scoping review. Drug Saf. 2022;45(5):477–91.
  11. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol. 2019;51(6):373–6.
  12. Desai MK. Artificial intelligence in pharmacovigilance–Opportunities and challenges. Perspect Clin Res. 2024;15(3):116–21.
  13. Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to structured real-world data for

pharmacovigilance purposes: Scoping review. J Med Internet Res. 2024;26:e57824.

  1. Baby A. Leveraging artificial intelligence in pharmacovigilance: Enhancing drug safety through data-driven approaches.
  2. Shukla D, Bhatt S, Gupta D, Verma S. Role of artificial intelligence in pharmacovigilance. J Drug Discov Health Sci. 2024;1(04):230–8.
  3. Choi YH, Han CY, Kim KS, Kim SG. Future directions of pharmacovigilance studies using electronic medical recording and human genetic databases. Toxicol Res. 2019;35:319–30.
  4. McCorvey A, Hale C. Advancing personalized medicine: Has genomic testing enhanced

pharmacovigilance to improve drug efficacy? J Interprof Educ Pract. 2017;7:65–71.

  1. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43(2):177–81.
  2. Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian J Pharmacol. 2015;47(1):65–71.
  3. Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: A systematic review. Int J Clin Pharm. 2023;45(6):1349–58.
  4. Grampp G, Felix T. Pharmacovigilance considerations for biosimilars in the USA. BioDrugs. 2015;29:309–21.
  5. Garcia-Gancedo L, Bate A. Digital biomarkers for post-licensure safety monitoring. Drug Discov Today. 2022;27(11):103354.
  6. Farid F, Ferdouszzaman M, Khan T, Sharma D. Advances in molecular biomarkers for

pharmacovigilance: Early detection of drug toxicity. World J Biol Pharm Health Sci. 2025;21:71–81.

  1. Liu F, Jagannatha A, Yu H. Towards drug safety surveillance and pharmacovigilance: Current progress in detecting medication and adverse drug events from electronic health records. Drug Saf. 2019;42(1):95–7.
  2. Segura-Bedmar I, Martínez P. Pharmacovigilance through the development of text mining and natural language processing techniques. J Biomed Inform. 2015;58:288–91.
  3. Zakari N, Al-Razgan M, Alsaadi A, Alshareef H, Alotaibi S. Blockchain technology in the pharmaceutical industry: A systematic review.
  4. Aher S, Mahajan M, Upaganlawar A, Upasani C. Pharmacovigilance in the digital age. Int J Pharm Sci. 2024;2(4):691–711.
  5. Anestina N, Obiageli C, Anthony O, Alade A, Mustapha A, Oluwaferanmi A. Ensuring drug safety: Comprehensive pharmacovigilance strategies for public health.
  6. Singh A, Twomey K, Baker R. Global pharmacovigilance regulations: Call for reharmonization. Clin Trials. 2018;15(6):631–2.
  7. Gettman D. Proactive pharmacovigilance: Leveraging predictive analytics and wearable health tech to manage medication-related risks in high-risk patient population. 2015.
  8. Bahk CY, Goshgarian M, Donahue K, Freifeld CC, Menone CM, Pierce CE, et al. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting Modernizing Pharmacovigilance: Leveraging AI, Automation, and Real-World Data for Drug Safety Rathod et al. applications: An analysis of adverse event reporting for the Essure device in the US. Pharm Med.2015;29:331–40.
  9. Silva L, Pacheco T, Araújo E, Duarte RJ, Ribeiro-Vaz I, Ferreira-da-Silva R. Unveiling the future: Precision pharmacovigilance in the era of personalized medicine. Int J Clin Pharm. 2024;46(3):755–60.
  10. Getov I, Panayotova D, Dobrev S, Dimitrova M, Petkova V. Opportunities for implementing digital applications to monitor the impact of risk-minimization measures within the pharmacovigilance process: Scoping review of published literature. Pharmacia. 2025;72:1–6.
  11. Yang J, Li F. The impact of technological progress on pharmacovigilance. Pharmacovigilance- Facts Challenges Limitations Opportunities. 2025:43
Ahead of Print Subscription Review Article
Volume 15
01
Received 12/09/2024
Accepted 07/02/2026
Published 07/03/2026
Publication Time 541 Days
80

Login


My IP

PlumX Metrics